tiprankstipranks
Esperion Announces CMO Transition and Continued Advisory Role
Company Announcements

Esperion Announces CMO Transition and Continued Advisory Role

Pick the best stocks and maximize your portfolio:

The latest update is out from Esperion (ESPR).

Esperion Therapeutics, Inc. has announced the departure of their Chief Medical Officer, Dr. JoAnne Foody, with a planned separation by September 16, 2024. Dr. Foody will transition to a Senior Advisor role and continue to earn her current salary until the separation date. Post-departure, she will receive a severance package including a year’s salary paid over 12 months, health insurance contributions, a prorated 2024 bonus, and an extension on exercising her vested stock options. Dr. Foody will also uphold her non-compete and confidentiality obligations and has provided a general release of claims to the company.

Learn more about ESPR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyMicron sinks on guidance, TripAdvisor to buy Liberty TripAdvisor: Morning Buzz
TheFlyMasterCard boosts dividend, Jabil reports Q1 beat: Morning Buzz
TheFlyEsperion closes refinancing transactions
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App